Cancer immunoprevention: From mice to early clinical trials

Arianna Palladini, Lorena Landuzzi, Pier Luigi Lollini, Patrizia Nanni

Research output: Contribution to journalReview article

Abstract

Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectively reduce cancer risk later in life. Successful primary immunoprevention of tumors caused by hepatitis B and papilloma viruses is already implemented at the population level with specific vaccines. The immunoprevention of human tumors unrelated to infectious agents is an outstanding challenge. Proof-of-principle preclinical studies in genetically-modified or in carcinogen-exposed mice clearly demonstrated that vaccines and other immunological treatments induce host immune responses that effectively control tumor onset and progression, eventually resulting in cancer prevention. While a straightforward translation to healthy humans is currently unfeasible, a number of pioneering clinical trials showed that cancer immunoprevention can be effectively implemented in human cohorts affected by specific cancer risks, such as preneoplastic/early neoplastic lesions. Future developments will see the implementation of cancer immunoprevention in a wider range of conditions at risk of tumor development, such as the exposure to known carcinogens and genetic predispositions.

Original languageEnglish
Article number16
Pages (from-to)1-6
Number of pages6
JournalBMC Immunology
Volume19
Issue number1
DOIs
Publication statusPublished - Jun 15 2018

Fingerprint

Clinical Trials
Neoplasms
Carcinogens
Vaccines
Papilloma
Human Development
Genetic Predisposition to Disease
Hepatitis B virus
Immune System
Population

Keywords

  • Cancer immunoprevention
  • Cancer vaccines
  • Genetically-modified mouse models
  • HER-2
  • Oncoantigens

ASJC Scopus subject areas

  • Immunology

Cite this

Cancer immunoprevention: From mice to early clinical trials. / Palladini, Arianna; Landuzzi, Lorena; Lollini, Pier Luigi; Nanni, Patrizia.

In: BMC Immunology, Vol. 19, No. 1, 16, 15.06.2018, p. 1-6.

Research output: Contribution to journalReview article

Palladini, Arianna ; Landuzzi, Lorena ; Lollini, Pier Luigi ; Nanni, Patrizia. / Cancer immunoprevention: From mice to early clinical trials. In: BMC Immunology. 2018 ; Vol. 19, No. 1. pp. 1-6.
@article{365220a574b748baa39887984774a822,
title = "Cancer immunoprevention: From mice to early clinical trials",
abstract = "Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectively reduce cancer risk later in life. Successful primary immunoprevention of tumors caused by hepatitis B and papilloma viruses is already implemented at the population level with specific vaccines. The immunoprevention of human tumors unrelated to infectious agents is an outstanding challenge. Proof-of-principle preclinical studies in genetically-modified or in carcinogen-exposed mice clearly demonstrated that vaccines and other immunological treatments induce host immune responses that effectively control tumor onset and progression, eventually resulting in cancer prevention. While a straightforward translation to healthy humans is currently unfeasible, a number of pioneering clinical trials showed that cancer immunoprevention can be effectively implemented in human cohorts affected by specific cancer risks, such as preneoplastic/early neoplastic lesions. Future developments will see the implementation of cancer immunoprevention in a wider range of conditions at risk of tumor development, such as the exposure to known carcinogens and genetic predispositions.",
keywords = "Cancer immunoprevention, Cancer vaccines, Genetically-modified mouse models, HER-2, Oncoantigens",
author = "Arianna Palladini and Lorena Landuzzi and Lollini, {Pier Luigi} and Patrizia Nanni",
year = "2018",
month = "6",
day = "15",
doi = "10.1186/s12865-018-0253-0",
language = "English",
volume = "19",
pages = "1--6",
journal = "BMC Immunology",
issn = "1471-2172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Cancer immunoprevention: From mice to early clinical trials

AU - Palladini, Arianna

AU - Landuzzi, Lorena

AU - Lollini, Pier Luigi

AU - Nanni, Patrizia

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectively reduce cancer risk later in life. Successful primary immunoprevention of tumors caused by hepatitis B and papilloma viruses is already implemented at the population level with specific vaccines. The immunoprevention of human tumors unrelated to infectious agents is an outstanding challenge. Proof-of-principle preclinical studies in genetically-modified or in carcinogen-exposed mice clearly demonstrated that vaccines and other immunological treatments induce host immune responses that effectively control tumor onset and progression, eventually resulting in cancer prevention. While a straightforward translation to healthy humans is currently unfeasible, a number of pioneering clinical trials showed that cancer immunoprevention can be effectively implemented in human cohorts affected by specific cancer risks, such as preneoplastic/early neoplastic lesions. Future developments will see the implementation of cancer immunoprevention in a wider range of conditions at risk of tumor development, such as the exposure to known carcinogens and genetic predispositions.

AB - Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectively reduce cancer risk later in life. Successful primary immunoprevention of tumors caused by hepatitis B and papilloma viruses is already implemented at the population level with specific vaccines. The immunoprevention of human tumors unrelated to infectious agents is an outstanding challenge. Proof-of-principle preclinical studies in genetically-modified or in carcinogen-exposed mice clearly demonstrated that vaccines and other immunological treatments induce host immune responses that effectively control tumor onset and progression, eventually resulting in cancer prevention. While a straightforward translation to healthy humans is currently unfeasible, a number of pioneering clinical trials showed that cancer immunoprevention can be effectively implemented in human cohorts affected by specific cancer risks, such as preneoplastic/early neoplastic lesions. Future developments will see the implementation of cancer immunoprevention in a wider range of conditions at risk of tumor development, such as the exposure to known carcinogens and genetic predispositions.

KW - Cancer immunoprevention

KW - Cancer vaccines

KW - Genetically-modified mouse models

KW - HER-2

KW - Oncoantigens

UR - http://www.scopus.com/inward/record.url?scp=85048600246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048600246&partnerID=8YFLogxK

U2 - 10.1186/s12865-018-0253-0

DO - 10.1186/s12865-018-0253-0

M3 - Review article

VL - 19

SP - 1

EP - 6

JO - BMC Immunology

JF - BMC Immunology

SN - 1471-2172

IS - 1

M1 - 16

ER -